We investigated the pharmacokinetics of ferulic acid, a potential antioxidant agent, after intravenous (i.v.) bolus administration in rats. To analyze ferulic acid levels in the plasma, bile, urine and tissue samples, we developed an HPLC-based method which was validated for a pharmacokinetic study by suitable criteria. After i.v. bolus administration of ferulic acid, it rapidly disappeared from blood circulation within 15 min. The mean plasma half-lives at α phase (t1/2α) when administered at doses of 2 and 10 mg/ kg were 1.10 and 1.39 min, respectively. The values of t1/2β at the corresponding doses increased 40% (from 5.02 to 7.01 min) with increasing doses. The total body clearance (CLt) values significantly decreased as the ferulic acid dose increased. On the other hand, steady-state volume of distribution (Vdss) values did not show the significant difference with the increase in dose. Of the various tissues, ferulic acid mainly distributed to the liver and kidney after i.v. bolus administration. The ferulic acid concentrations in various tissues at 2 hr after i.v. bolus administration were below 1.0 μg/g tissue. Ferulic acid was excreted in the bile and urine after i.v. bolus administration at the dose of 10 mg/kg. The cumulative amount of ferulic acid in the bile 2 hr after dosage was comparable with the amount excreted in the urine after 72 hr, indicating that i.v. administered ferulic acid was mainly excreted in the both bile and urine. In conclusion, ferulic acid was rapidly cleared from the circulating blood and transferred to tissues such as the liver and kidney after i.v. bolus administration. Moreover, the majority of ferulic acid appears to be excreted in the bile and urine after i.v. bolus administration.

The 34 potently pig pheromonal odorants (1-32, 5755 & 7113) through structure-based virtual screening and ligand-based virtual screening method were selected and their ADMET and pharmacokinetics characters were evaluated and discussed quantitatively. The pheromonal odorants were projected on the following pre-calculated models, Caco-2 cell permeability, blood-brain barrier permeation, hERG inhibition and volume-distribution. From the results of in silico study, it is found that an optimal compound (31) either penetrating or have a little (Pcaco2=－8.143) for Caco-2 cell permeability, moderate penetrating ability (PBBB=0.082) for blood-brain barrier permeation, the low QT prolongation (PhERG=1.137) for the hERG K+ channel inhibition, and low distribution into tissues (PVD=－5.468) for volume-distribution. Therefore, it is predicted that the compound (31) a topical application may be preferable from these based foundings.